Caspofungin

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
65041
A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin (CASP) in the First-line Treatment of probable and proven Invasive Aspergillosis 'IA) in Patients with Hematological Malignances (HM) or recipients of autologous Haematopoietic Stem Cell Transplantation and those with allogeneic Haematopoietic Stem Cell Transplantation (HSCT)

Back to Protocol section